Novavax, Inc. (NASDAQ:NVAX) – Experts See The Stock A Different Way Today

In the last trading session, 4.43 million shares of the Novavax, Inc. (NASDAQ:NVAX) were traded, and its beta was 1.61. Most recently the company’s share price was $4.53, and it changed around -$0.12 or -2.58% from the last close, which brings the market valuation of the company to $633.97M. NVAX currently trades at a discount to its 52-week high of $11.36, offering almost -150.77% off that amount. The share price’s 52-week low was $3.53, which indicates that the current value has risen by an impressive 22.08% since then. We note from Novavax, Inc.’s average daily trading volume that its 10-day average is 4.32 million shares, with the 3-month average coming to 8.56 million.

Novavax, Inc. stock received a consensus recommendation rating of Hold, based on a mean score of 2.50. If we narrow it down even further, the data shows that 0 out of 7 analysts rate the stock as a Sell; another 2 rate it as Overweight. Among the rest, 5 recommended NVAX as a Hold, whereas 0 deemed it a Buy, and 0 rated it as Underweight. Novavax, Inc. is expected to report earnings per share of -$0.95 for the current quarter.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free

Novavax, Inc. (NASDAQ:NVAX) trade information

Instantly NVAX has showed a red trend with a performance of -2.58% at the end of last trading. The performance over the last five days has remained in the red territory. The company’s shares are currently down -5.62% year-to-date, but still down -5.82% over the last five days. On the other hand, Novavax, Inc. (NASDAQ:NVAX) is -15.96% down in the 30-day period. We can see from the shorts that 48.13 million shares have been sold at a short interest cover period of 4.04 day(s).

The consensus price target as assigned by Wall Street analysts is $174, which translates to bulls needing to increase their stock price by 97.4% from its current value. Analyst projections state that NVAX is forecast to be at a low of $174 and a high of $174.

Novavax, Inc. (NVAX) estimates and forecasts

Novavax, Inc. share prices are performing particularly well compared to other companies within the same industry. As is evident from the statistics, the company’s shares have fallen -37.43 percent over the past six months and at a 83.73% annual growth rate that is well above the industry average of 13.60%. Moreover, analysts have decided to roll up on their fiscal year 2024 revenue estimates. The rating firms predict that it will gain 72.10% in revenue this quarter, and will report a decrease of -277.60% in the next quarter. The year-over-year growth rate is expected to be -13.60%, down from the previous year.

Consensus estimates provided by 4 financial analysts predict the company will bring in an average of $101.45 million in revenue for the current quarter. 4 analysts expect Novavax, Inc. to make $76.65 million in revenue for the quarter ending Jun 2024. Analysts predict that the company’s current quarter sales will jump, forecast at 25.30%.

Looking at the company’s year-over-year earnings, the past five years showed a positive earnings growth rate of 11.55%.

NVAX Dividends

Novavax, Inc.’s next quarterly earnings report is expected to be released around May 07 and May 13.

Novavax, Inc. (NASDAQ:NVAX)’s Major holders

Upon looking at major shareholders, it appears that insiders hold 4.99% of Novavax, Inc. shares, and 56.31% of them are in the hands of institutional investors. The stock currently has a share float of 59.27%. Novavax, Inc. stock is held by 277 institutions, with State Street Corporation being the largest institutional investor. By Jun 29, 2023, it held 12.37% of the shares, which is about 11.68 million shares worth $86.78 million.

Vanguard Group Inc, with 11.20% or 10.57 million shares worth $78.55 million as of Jun 29, 2023, holds the second largest percentage of outstanding shares.

SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF and Vanguard Total Stock Market Index Fund were the top two Mutual Funds as of Aug 30, 2023. The former held 9.38 million shares worth $75.07 million, making up 9.94% of all outstanding shares. On the other hand, Vanguard Total Stock Market Index Fund held roughly 2.64 million shares worth around $19.6 million, which represents about 2.79% of the total shares outstanding.